Xiang Shu

Assistant Attending

Epidemiology & Biostatistics
Directory
Epidemiology
Biostatistics
Health Outcomes
Computational Oncology
Administrative Resources
Departmental Newsletter
Career Opportunities
Quantitative Sciences Undergraduate Research Experience (QSURE)
Software
Bridge to Biostats

Xiang Shu

Assistant Attending

Share
Print
Share
Print
Xiang Shu

Email

shux@mskcc.org

Dr. Shu’s research primarily focuses on identifying novel genetic and molecular markers for cancer risk, with the goal of better understanding tumorigenesis and providing novel tools for risk assessment. Dr. Shu is actively participating in multiple international consortia including the Breast Cancer Association Consortium, the Asia Breast Cancer Consortium, the Genetics and Epidemiology of Colorectal Cancer Consortium. Dr. Shu recently received an R00 grant, which aims to provide new insights into the etiology of colorectal cancer and identify novel risk biomarkers for this malignancy via integrated omics approaches. He is also an active investigator in three large prospective cohorts, the Shanghai Women’s Health Study (SWHS), the Shanghai Men’s Health Study (SMHS), and the Southern Community Cohort Study (SCCS), leading several prospective metabolomics and proteomics projects in these cohorts. These projects provided solid preliminary data to support further investigations to uncover novel risk biomarkers for colorectal, pancreatic, and gastric cancers. With the contribution of resources from several established prospective cohorts, including SWHS/SMHS, SCCS, the Multiethnic Cohort Study, the European Prospective Investigation into Cancer and Nutrition Study, and the Women’s Health Initiative, Dr. Shu has formed an international consortium to investigate the relationship between perturbation of blood metabolome and risk of incident gastric cancer. After joining the department in August, Dr. Shu has also extended his interest to patient-oriented research by contributing his expertise in genetic and molecular epidemiology.

Publications

  1. Shu X, Long J, Cai Q, Kweon SS, Choi JY, Kubo M, Park SK, Humphreys M, Dennis J, Wang Q, Yang Y, Shi J, Guo X, Li B, Tao R, Aronson K, Chan K, Chan T, Gao Y, Hartman M, Ho WK, Ito H, Iwasaki M, Iwata H, John E, Kasuga Y, Khoo US, Kim MK, Kong SY, Kurian A, Kwong A, Lee ES, Li J, Lophatananon A, Low S-K, Mariapun S, Matsuda K, Matsuo K, Muir K, Noh DY, Park B, Park MH,  Shen CY, Shin MH, Spinelli J, Takahashi A, Tseng C, Tsugane S, Wu A, Xiang YB, Yamaji T, Zheng Y, Milne R, Dunning A, Pharoah P, Garcia-Closas M, Teo SH, Shu XO, Kang D, Easton D, Simard J. Zheng W. Identification of novel breast cancer susceptibility loci in meta-analyses conducted among Asian and European descendants. Nat Commun. 2020 Mar 5;11(1):1217
  2. Shu X, Bao J, Wu L, Long J, Shu XO, Guo X, Yang Y, Michailidou K, Bolla MK, Wang Q, Dennis J, Andrulis IL, Castelao JE, Dörk T, Gago-Dominguez M, García-Closas M, Giles GG, Lophatananon A, Muir K, Olsson H, Rennert G, Saloustros E, Scott RJ, Southey MC, Pharoah PDP, Milne RL, Kraft P, Simard J, Easton DF, Zheng W. Evaluation of associations between genetically predicted circulating protein biomarkers and breast cancer risk. Int J Cancer. 2020 Apr 15;146(8):2130-2138
  3. Wang F, Shu X, Meszoely I, Pal T, Mayer IA, Yu Z, Zheng W, Bailey CE, Shu XO. Overall Mortality After Diagnosis of Breast Cancer in Men vs Women. JAMA Oncol. 2020;6(3):442.
  4. Shu X, Wu L, Khankari NK, Shu XO, Wang TJ, Michailidou K, Bolla MK, Wang Q, Dennis J, Milne RL, Schmidt MK, Pharoah PDP, Andrulis IL, Hunter DJ, Simard J, Easton DF, Zheng W, Breast Cancer Association Consortium. Associations of obesity and circulating insulin and glucose with breast cancer risk: A Mendelian randomization analysis. Int J Epidemiol. 2019 Jun 1;48(3):795-806
  5. Shu X, Xiang YB, Rothman N, Yu D, Li HL, Yang G, Cai H, Ma X, Lan Q, Gao YT, Jia W, Shu XO, Zheng W. Prospective study of blood metabolites associated with colorectal cancer risk. Int J Cancer. 2018 Aug 1;143(3):527-534

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Xiang Shu discloses the following relationships and financial interests:

No disclosures meeting criteria for time period


The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.


View all disclosures